Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4520769
Max Phase: Preclinical
Molecular Formula: C22H28N8O6
Molecular Weight: 500.52
Molecule Type: Unknown
Associated Items:
ID: ALA4520769
Max Phase: Preclinical
Molecular Formula: C22H28N8O6
Molecular Weight: 500.52
Molecule Type: Unknown
Associated Items:
Canonical SMILES: NC(=O)c1cccc(CN(CC[C@H](N)C(=O)O)C[C@H]2O[C@@H](n3cnc4c(N)ncnc43)[C@H](O)[C@@H]2O)c1
Standard InChI: InChI=1S/C22H28N8O6/c23-13(22(34)35)4-5-29(7-11-2-1-3-12(6-11)19(25)33)8-14-16(31)17(32)21(36-14)30-10-28-15-18(24)26-9-27-20(15)30/h1-3,6,9-10,13-14,16-17,21,31-32H,4-5,7-8,23H2,(H2,25,33)(H,34,35)(H2,24,26,27)/t13-,14+,16+,17+,21+/m0/s1
Standard InChI Key: MEMKBIDVNKYNQW-QMBVYZDCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 500.52 | Molecular Weight (Monoisotopic): 500.2132 | AlogP: -1.57 | #Rotatable Bonds: 10 |
Polar Surface Area: 228.96 | Molecular Species: ZWITTERION | HBA: 12 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 14 | HBD (Lipinski): 9 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 2.80 | CX Basic pKa: 9.19 | CX LogP: -4.15 | CX LogD: -4.14 |
Aromatic Rings: 3 | Heavy Atoms: 36 | QED Weighted: 0.19 | Np Likeness Score: 0.08 |
1. Gao Y, van Haren MJ, Moret EE, Rood JJM, Sartini D, Salvucci A, Emanuelli M, Craveur P, Babault N, Jin J, Martin NI.. (2019) Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT) with Enhanced Activity., 62 (14): [PMID:31265285] [10.1021/acs.jmedchem.9b00413] |
2. Policarpo RL, Decultot L, May E, Kuzmič P, Carlson S, Huang D, Chu V, Wright BA, Dhakshinamoorthy S, Kannt A, Rani S, Dittakavi S, Panarese JD, Gaudet R, Shair MD.. (2019) High-Affinity Alkynyl Bisubstrate Inhibitors of Nicotinamide N-Methyltransferase (NNMT)., 62 (21): [PMID:31589440] [10.1021/acs.jmedchem.9b01238] |
3. Gao Y, van Haren MJ, Buijs N, Innocenti P, Zhang Y, Sartini D, Campagna R, Emanuelli M, Parsons RB, Jespers W, Gutiérrez-de-Terán H, van Westen GJP, Martin NI.. (2021) Potent Inhibition of Nicotinamide N-Methyltransferase by Alkene-Linked Bisubstrate Mimics Bearing Electron Deficient Aromatics., 64 (17.0): [PMID:34424711] [10.1021/acs.jmedchem.1c01094] |
4. Iyamu ID, Huang R.. (2021) Mechanisms and inhibitors of nicotinamide N-methyltransferase., 12 (8.0): [PMID:34458733] [10.1039/D1MD00016K] |
Source(1):